NCT04519424撤回2 期
A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- CSL Behring
- 主要终点
- Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation
研究概览
简要总结
This is a phase 2, prospective, multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the safety and efficacy of intravenous (IV) administration of CSL324, administered in combination with SOC treatment, in subjects with COVID 19.
For the purposes of this study, standard of care (SOC) may include any written or established treatment protocol followed at the study site for the treatment of severe COVID-19 or its complications, including off-label use of marketed pharmaceutical products and / or products with emergency use authorization granted for the treatment of COVID-19 (ie, not yet marketed) (eg, remdesivir).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years at the time informed consent is obtained
- •Positive for SARS-CoV-2 infection determined by a diagnostic test approved by the Food and Drug Administration (FDA) or allowed under an emergency use authorization
- •Chest computed tomography (CT) scan or X ray results confirming interstitial pneumonia
- •Meets ≥ 1 of the following criteria (subjects improving while on respiratory support still qualify):
- •Respiratory rate > 30 breaths per minute
- •Peripheral (capillary) oxygen saturation (SpO2) ≤ 93% on room air
- •Partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) ratio (PaO2 / FiO2) < 300
- •SpO2 / FiO2 ratio < 218 (if PaO2 / FiO2 ratio is not available)
- •Radiographic lung infiltrates > 50%
排除标准
- •Currently enrolled, planning to enroll, or participated, within the last 30 days, in a clinical study requiring administration of an investigational product (ie, not yet marketed), including expanded access or compassionate use
- •Exceptions:
- •Administration of investigational product with emergency use authorization granted for treatment of COVID 19 (eg, remdesivir) is permitted
- •Convalescent plasma as part of approved special access programs such as expanded access, emergency IND, or compassionate use is permitted
- •Pregnant or breastfeeding (female subjects)
- •Intubated and requires mechanical ventilation (including ECMO) at time of randomization
- •Exception: use of HFNC oxygen and noninvasive ventilation are permitted
- •Endotracheal intubation is imminent, in the opinion of the investigator
- •Not expected to survive for more than 48 hours after hospital admission, in the opinion of the investigator
- •Presence of any of the following comorbid conditions before randomization and prior to SARS-CoV-2 infection:
- •New York Heart Association class IV heart failure
- •Stage 4 or 5 chronic kidney disease or requires renal replacement therapy
- •Biopsy proven cirrhosis, portal hypertension or hepatic encephalopathy
- •Stage IV malignancy
- •Chronic lung disease requiring home oxygen
- •Active tuberculosis
- •History or evidence of pulmonary alveolar proteinosis
- •Confirmed diagnosis or clinical suspicion of bacterial pneumonia or active uncontrolled bacterial, fungal, or non SARS-CoV-2 viral infection at Screening
- •Absolute neutrophil count (ANC) value < 5 × 109 cells/L at Screening (can be lowered up to < 1.5 × 109 cells/L after Independent Data Monitoring Committee review of safety data, if CSL324 induced neutropenia is not assessed as a safety concern)
- •Currently receiving a prohibited therapy including G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), or antibody against interleukin 6 (IL-6) / IL 6 receptor (anti IL-6 / 6R)
研究组 & 干预措施
CSL324
Experimental
CSL324 administered intravenously
干预措施: CSL324 (Biological)
Placebo
Placebo Comparator
Normal saline administered intravenously
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation
时间窗: Randomization to Day 28
次要结局
- Proportion of subjects using high-flow nasal cannula (HFNC)(Randomization to Day 28)
- Proportion of subjects using extracorporeal membrane oxygenation (ECMO)(Randomization to Day 28)
- Proportion of deaths from all causes(Randomization to Day 28)
- Proportion of subjects intubated(Randomization to Day 28)
- Number and proportion of subjects with at least a 2-point improvement in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale(Randomization to Day 28)
- Median length of stay in hospital(Randomization to Day 28)
- Number and proportion of subjects within each of the categories of the NIAID ordinal scale(Daily up to Day 28)
- Proportion of subjects using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP)(Randomization to Day 28)
- Maximum Change in Sequential Organ Failure Assessment (SOFA) score(Randomization to Day 28)
- Change in SOFA score and in individual components of the SOFA score(Baseline to Day 28)
- Number and proportion of subjects experiencing adverse events (AEs)(Up to 60 days)
- Number and proportion of subjects experiencing serious adverse events (SAEs)(Up to 60 days)
- Number and proportion of subjects experiencing adverse events of special interest (AESIs)(Up to 60 days)
- Presence of anti-CSL324 antibodies(Up to 28 days)
- Maximum concentration (Cmax) of CSL324(Up to 28 days)
- Time to reach maximum concentration (Tmax) of CSL324(Up to 28 days)
- Trough concentration (Ctrough) of CSL324(Before dose on Day 4 and Day 8)
- Area under the concentration-time curve (AUC0-last) of CSL324(Up to 28 days)
研究者
相似试验
已完成
2 期
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)Coronavirus Disease 2019 (COVID-19)NCT04409509CSL Behring124
暂停
2 期
A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic StrokesIschemic StrokeNCT02785120Techfields Inc225
已完成
2 期
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial InfarctionModerate Renal ImpairmentAcute Myocardial InfarctionNCT02742103CSL Behring83
已完成
2 期
HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)Age-Associated Memory Impairment (AAMI)NCT02013310Dart NeuroScience, LLC119
已完成
2 期
A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With OsteoarthritisOsteoarthritis of the KneeNCT02067611Lina Xu216